Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

 
• By Xu Hu

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

lung cancer
Fosun's ALK/ROS1 inhibitor meets primary endpoint in Phase III for ALK+ advanced NSCLC • Source: Shutterstock

More from Clinical Trials

More from R&D